Brivaracetam: Rationale for discovery and preclinical profile of a selective SV 2A ligand for epilepsy treatment
Author:
Affiliation:
1. UCB Pharma Braine l'Alleud Belgium
Funder
UCB Pharma
Publisher
Wiley
Subject
Clinical Neurology,Neurology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/epi.13340
Reference83 articles.
1. Prognosis of Epilepsy: A Review and Further Analysis of the First Nine Years of the British National General Practice Study of Epilepsy, a Prospective Population-Based Study
2. Early Identification of Refractory Epilepsy
3. Patterns of treatment response in newly diagnosed epilepsy
4. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial
5. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial
Cited by 130 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Favorable combinations of antiseizure medication with vagus nerve stimulation to improve health-related quality of life in patients with epilepsy;Epilepsy & Behavior;2024-01
2. Identification of degradation products of brivaracetam using liquid chromatography quadrupole time‐of‐flight tandem mass spectrometry: Degradation pathway elucidation;Rapid Communications in Mass Spectrometry;2023-11-21
3. Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil;Neuroscience Bulletin;2023-10-28
4. Effect of intranasal and oral administration of levetiracetam on the temporal and spatial distributions of SV2A in the KA‐induced rat model of SE;Journal of Cellular and Molecular Medicine;2023-10-16
5. An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes;Frontiers in Neurology;2023-10-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3